BARRY MICHAEL BERNSTEIN
Pilots at Wyngate Trce, Thiensville, WI
License number
Wisconsin A2687172
Issued Date
Nov 2015
Expiration Date
Nov 2017
Category
Airmen
Type
Authorized Aircraft Instructor
Address
Address
10829 N Wyngate Trce, Thiensville, WI 53092
Professional information
Methods For Treating Hcv
US Patent:
2014002, Jan 23, 2014
Filed:
Jun 26, 2013
Appl. No.:
13/927814
Inventors:
Thomas J. PODSADECKI - Northbrook IL, US
Barry M. BERNSTEIN - Mequon WI, US
Martin S. KING - Lincolnshire IL, US
Barry M. BERNSTEIN - Mequon WI, US
Martin S. KING - Lincolnshire IL, US
International Classification:
A61K 31/7068, A61K 31/497, A61K 31/407, A61K 31/427, A61K 31/4025, A61K 45/06, A61K 31/7056, A61K 31/513
US Classification:
514 49, 514 43, 51425505, 514274, 514365, 514422
Abstract:
In one aspect, the present invention features HCV therapies comprising administering to a patient in need thereof an HCV protease inhibitor and ritonavir, wherein ritonavir is used as a pharmacokinetic booster to improve the pharmacokinetics of the HCV protease inhibitor. The HCV therapies do not require the testing of total cholesterol and triglyceride levels prior to and after the therapies.
Methods For Treating Hcv
US Patent:
8492386, Jul 23, 2013
Filed:
Sep 4, 2012
Appl. No.:
13/603006
Inventors:
Barry M. Bernstein - Mequon WI, US
Rajeev M. Menon - Buffalo Grove IL, US
Amit Khatri - Waukegan IL, US
Sven Mensing - Mannheim, DE
Sandeep Dutta - Gurnee IL, US
Daniel E. Cohen - Wilmette IL, US
Thomas J. Podsadecki - Chicago IL, US
Scott C. Brun - Green Oaks IL, US
Walid M. Awni - Green Oaks IL, US
Emily O. Dumas - Libertyville IL, US
Cheri E. Klein - Northbrook IL, US
Rajeev M. Menon - Buffalo Grove IL, US
Amit Khatri - Waukegan IL, US
Sven Mensing - Mannheim, DE
Sandeep Dutta - Gurnee IL, US
Daniel E. Cohen - Wilmette IL, US
Thomas J. Podsadecki - Chicago IL, US
Scott C. Brun - Green Oaks IL, US
Walid M. Awni - Green Oaks IL, US
Emily O. Dumas - Libertyville IL, US
Cheri E. Klein - Northbrook IL, US
Assignee:
AbbVie Inc. - North Chicago IL
International Classification:
A61K 31/4965, A61K 31/33, A61K 31/505, A61K 31/47, A61K 31/415, A61K 31/40, A61K 31/675
US Classification:
51425505, 514183, 514269, 514314, 514397, 514309, 514394, 514422, 514 81
Abstract:
The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e. g. , ritonavir).
Methods For Treating Hcv
US Patent:
8466159, Jun 18, 2013
Filed:
Sep 4, 2012
Appl. No.:
13/603022
Inventors:
Barry M. Bernstein - Mequon WI, US
Rajeev M. Menon - Buffalo Grove IL, US
Amit Khatri - Waukegan IL, US
Sven Mensing - Mannheim, DE
Sandeep Dutta - Gurnee IL, US
Daniel E. Cohen - Wilmette IL, US
Thomas J. Podsadecki - Chicago IL, US
Scott C. Brun - Green Oaks IL, US
Walid M. Awni - Green Oaks IL, US
Emily O. Dumas - Libertyville IL, US
Cheri E. Klein - Northbrook IL, US
Rajeev M. Menon - Buffalo Grove IL, US
Amit Khatri - Waukegan IL, US
Sven Mensing - Mannheim, DE
Sandeep Dutta - Gurnee IL, US
Daniel E. Cohen - Wilmette IL, US
Thomas J. Podsadecki - Chicago IL, US
Scott C. Brun - Green Oaks IL, US
Walid M. Awni - Green Oaks IL, US
Emily O. Dumas - Libertyville IL, US
Cheri E. Klein - Northbrook IL, US
Assignee:
AbbVie Inc. - North Chicago IL
International Classification:
A61K 31/4965, A61K 31/33, A61K 31/505, A61K 31/47, A61K 31/415, A61K 31/40
US Classification:
51425505, 514183, 514269, 514314, 514397, 514309, 514394, 514422, 514 81
Abstract:
The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e. g. , ritonavir), and ribavirin.
Methods For Treating Hcv
US Patent:
2013007, Mar 21, 2013
Filed:
Sep 17, 2012
Appl. No.:
13/621454
Inventors:
Barry M. Bernstein - Mequon WI, US
Scott C. Brun - Green Oaks IL, US
Scott C. Brun - Green Oaks IL, US
Assignee:
ABBVIE INC. - North Chicago IL
International Classification:
A61K 31/427, A61P 31/14
US Classification:
514365
Abstract:
The present invention features interferon-free therapies for the treatment of HCV. The therapies comprise administering Compound I (or a pharmaceutically acceptable salt thereof) and another anti-HCV agent. Preferably, the therapies are both interferon- and ribavirin-free.